Transforming Anorexia Nervosa Treatment
We are pioneering a breakthrough approach to treating anorexia nervosa through the repurposing of metreleptin, offering new hope to patients and families affected by this devastating condition.
Anorexia is a serious medical illness impacting more that 400,000 people every year in the US alone.
π§βπ§βπ§
Anorexia affects ~1% of women, typically emerging during adolescence
π
It has the highest mortality rate of any mental health disorder (5-10%)
π
Currently, there are NO FDA-approved medications for treating anorexia nervosa
π²
Only 1 in 100 patients receives specialized care due to prohibitive costs
Our Mission
At Zula Therapeutics, we're committed to developing an effective medication for anorexia nervosa, the deadliest mental health disorder, and ensuring it's accessible to all who need it. As a public benefit corporation, we balance purpose with profit to bring this life-changing treatment to market with patient access as our priority.
Partnering for Impact
Zula Therapeutics has joined forces with Mount Sinai's Center of Excellence in Eating and Weight Disorders to advance metreleptin treatment for anorexia nervosa through clinical trials. This powerful collaboration combines cutting-edge research with clinical expertise to accelerate patient access to this promising therapy.